admin, Author at PsyNews.com

Home Authors Posts by admin

2176 POSTS 0 COMMENTS

https://psynews.com

Psychedelic Bulletin #110 – Psychedelics Docuseries Comes to Netflix; DEA Schedules...

FILAMENT HEALTH ANNOUNCES FIRST DOSING IN GROUNDBREAKING FDA-APPROVED PSILOCIN CLINICAL TRIAL

PT335 – Christopher Dawson & Andrew Galloway – Modernizing Traditional Plant...

Tripping the Reward Circuit: Psychedelics for Substance Use Disorders

Psychedelic Drugs Market Reaches US$6330.0 Mn by 2026 from US$3210.0 Mn...

Algernon Pharmaceuticals Provides Update on Its Phase 1 DMT Stroke Study

Numinus to Host Q3 2022 Results Conference Call on July 14,...

Algernon Pharmaceuticals Discloses Novel DMT Salt Patent Strategy Includes Bioactive Nicotinate...

FILAMENT HEALTH ANNOUNCES SIXTH PATENT ISSUANCE

Mindset Pharma Receives Allowance for Patent Application Covering its Short-Duration Novel...

1...135136137...218 Page 136 of 218

EDITOR PICKS

After the Readout: How the Field Is Interpreting Compass’ Phase 3...

Q1’26 Psychedelic Drug Development Pipeline: Bullseye Charts

Compass Provides Fuller Phase 3 Picture, MADRS Curves, on Webcast

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

admin